RecruitingPhase 3NCT07326709

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

Sponsor

Novartis Pharmaceuticals

Enrollment

770 participants

Start Date

Mar 24, 2026

Study Type

INTERVENTIONAL

Conditions

Huntington Disease

Summary

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.

Eligibility

Min Age: 21 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Votoplam (blinded) for people with huntington disease. The study is currently recruiting participants at 20 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVotoplam (blinded)

Votoplam (blinded) active treatment

DRUGPlacebo

Placebo

Locations(41)

University of CA San Diego

La Jolla, California, United States

CenExcel Rocky Mtn Clin Research

Englewood, Colorado, United States

Georgetown University

Washington D.C., District of Columbia, United States

University Of South Florida

Tampa, Florida, United States

Parkinsons-Movement Disorder Ctr

Chicago, Illinois, United States

Indiana University Health

Indianapolis, Indiana, United States

University of Iowa Health Care

Iowa City, Iowa, United States

University of Kansas Hospital

Fairway, Kansas, United States

Trinity Health Michigan

Grand Rapids, Michigan, United States

Albany Medical College

Albany, New York, United States

UBMD Neurology

Buffalo, New York, United States

Columbia University Irving Medical

New York, New York, United States

Universi of Rochester School of Med

Rochester, New York, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Veracity Neuroscience LLC

Memphis, Tennessee, United States

Vanderbilt University Medical CenterX

Nashville, Tennessee, United States

TX Movement Disorder Spec PLLC

Georgetown, Texas, United States

U of TX Health Science Ct

Houston, Texas, United States

The University of Vermont MC

Burlington, Vermont, United States

University of Washington Medical Center

Seattle, Washington, United States

Novartis Investigative Site

CABA, Buenos Aires, Argentina

North York General Hospital

North York, Ontario, Canada

Centre de recherche du CHUM

Montreal, Quebec, Canada

CUSM Montreal Neurological Institute

Montreal, Quebec, Canada

Novartis Investigative Site

Chengdu, Sichuan, China

Tel Aviv Sourasky Med Ctr Ichilov

Tel Aviv, Israel

Novartis Investigative Site

Dongjak Gu, Seoul, South Korea

Novartis Investigative Site

Seoul, Seoul, South Korea

Novartis Investigative Site

Busan, South Korea

Novartis Investigative Site

Basel, Switzerland

Novartis Investigative Site

Muri bei Bern, Switzerland

Novartis Investigative Site

Changhua, Taiwan

Novartis Investigative Site

Taipei, Taiwan

Novartis Investigative Site

Exeter, Devon, United Kingdom

Novartis Investigative Site

Aberdeen, Grampian Region, United Kingdom

Novartis Investigative Site

Cardiff, United Kingdom

Novartis Investigative Site

Glasgow, United Kingdom

University College Hospital

London, United Kingdom

Novartis Investigative Site

Oxford, United Kingdom

Southampton General Hospital

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07326709

Related Trials

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

NCT0737864419 locations

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

NCT0666741445 locations

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

NCT068266125 locations

Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease

NCT075138441 location

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

NCT0687333412 locations